Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of enzalutamide with standard therapy in newly diagnosed glioblastoma
MOH_2023-04-30_012586Phase 2Not yet recruiting
- Sponsor
- פרופ אלכסנדר לוסוס
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in glioblastoma (GBM), sponsored by פרופ אלכסנדר לוסוס. Primary endpoint: Primary endpoint not specified. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2023-04-30_012586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-30_012586.